The goal of the app is to maintain proper control of the disease and notify healthcare professionals through visible alarms on the dashboard that they review themselves. Thanks to this warning, it is possible to act early, since it can alert up to 18 days before a patient’s decompensation occurs.
The first real test of the program begins this March thanks to the participation of more than 50 patients and will focus on teaching the operation of the diagnostic tool to Hospital de Bellvitge and IDIBELL professionals, the monitoring of patient follow-up and the generation of alerts, as well as the training of the patients themselves.
The objective of this pilot test, which will be carried out for 6 or 9 months, is to assess the feasibility of using the tool, which has already been validated in Israel and the United States and has been able to predict 79.6% of relapses in patients with congestive heart failure up to 18 days before they occur.
The clinical leadership of this pilot by the Hospital Universitario de Bellvitge is key, as it develops high-quality integrated care for patients with heart failure within a Territorial Program of Integrated Care with Primary Care dedicated to this pathology, which has shown reduce mortality and hospitalizations of these patients.
Heart failure is a chronic condition characterized by the inability to pump blood through the body effectively. This pathology affects 2.34% of the Spanish adult population and is the main cause of hospitalization in people over 65 years of age. It is essential to establish an early approach and continuous monitoring of the patient’s condition to keep symptoms under control, avoid hospital admissions and improve her quality of life.
HearOTM is a digital solution that turns mobile phones into advanced medical devices. Through its innovative technology, different speech samples from patients are monitored, creating a learning of the speech model through artificial intelligence, which will allow analyzing the differences and detecting changes related to heart failure and alerting the doctor, allowing acting fast and efficiently.
Bioheart, cardiovascular disease research group
The BIO-HEART Cardiovascular Disease Research Group is a renewed emerging group within the Research Program on inflammatory, chronic and degenerative diseases of the Translational Research Area of IDIBELL (Bellvitge Biomedical Research Institute) led by Dr. Josep Comin Colet. It is a multidisciplinary research group made up of health professionals dedicated to the management and prevention of cardiovascular diseases.
The research team includes basic postdoctoral researchers, clinical and interventional cardiologists, specialized nurses, community medicine professionals, and cardiologists specializing in imaging techniques for the diagnosis of coronary artery disease and heart failure from Bellvitge University Hospital.
The BIO-HEART research group supports its research activity in a solid cardiovascular research cluster formed in the South Metropolitan health region, which includes 8 hospital centers, coordinated by the Bellvitge University Hospital, and more than 60 primary care centers that form a care and research center, network that provides standard high-quality care services to more than 1.5 million people and serves as a platform for clinical and preclinical studies promoted and coordinated by the group. Its main objective is to reduce the risk of cardiovascular diseases by conducting applied and translational research.